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Abstract 
Alzheimer's disease (AD) is a neurodegenerative disease commonly found in the aging 
populations. The disease is characterized by memory loss and cognitive impairment 
mainly due to a severe loss of cholinergic neuron. This also results in a deficit in the 
acetylcholine (ACh) neurotransmission. At present, the only drugs licensed to treat AD 
are invariably inhibitors of acetylcholinesterase (AChE). Most of these drugs such as 
tacrine and galanthamine are originally isolated from plants. In this study, the AChE 
inhibition activities of selected Chinese medicinal herbs that have been clinically 
prescribed for treating dementia and mental disorders were tested. 
Effect of selected Chinese medicinal herbs on AChE activity was determined by the 
colorimetric Ellman assay. By screening 45 selected Chinese medicinal herbs, the 
ethanol and aqueous extracts of Bai Shao, Chi Shao, Da Huang, He Shou Wu, Ji Xue 
Teiig and Danshen were found to have high inhibitory activity of AChE. Further 
investigation indicated that, the ethanol extract (50 |lg/ml) of Salvia miltiorrhiza 
(Danshen ) showed 90 % inhibition against human AChE while the aqueous extract has 
50 % inhibition at the same concentration. Six commercially available active 
components of Salvia miltiorrhiza was further investigated and cryptotanshinone and 
dihydrotanshinone I gave a prominent AChE inhibition with IC50 at around 5|iM and 
0.5)iM respectively. Assay of the two compounds on butrylcholinesterase (liBChE)-
a pesudoesterase that is abundant in red blood cell and shares a very high homology to 
hAChE, also showed that they were specific inhibitors to hAChE. 
In order to obtain the chemical profile of Salvia miltiorrhiza, reverse phase high 
performance liquid chromotograph (RP-HPLC) was used. We obtained the chemical 
ii 
profile of our Danshen ethanol extract, which are mainly composed of 6 active 
ingredients of compounds. We also incorporated RP-HPLC and the use of sep-pak© 
cartridges and concentrate the desired portion that were rich in our desired active 
components that results in the inhibition of acetylcholinesterase in our study. 
Cryptotanshinone was successfully purified and the purified cryptotanshinone were also 
found to inhibit hAChE in the same extend as to the commercially obtained stock. 
Comparison of Danshen from different sources was also revealed in this thesis and we 
found that processed Danshen from Sichuan are rich in cryptotanshinone and 
dihydrotanshinone I，when compare with Danshen from Danshen from Heibei or the 
unprocessed Sichuan Danshen. Effect of ethanol concentration on active component 
extraction was also elucidated. 
The less cytotoxic drug cryptotanshinone was then tested with calcium fluorimetry to 
elucidate its potential as nicotinic receptor allosterically potentiating ligand (APL). It is 
found that cryptotanshinone can alter the fast channel opening of human neuroblastoma 
cell line SH-SY5Y nicotinic receptors, resulting in the delaying of fast calcium influx. 
The results indicating the potential for cryptotanshinone to act as an AChE inhibitor and 
nicotinic receptor modulator, that function similarly as galanthamine, but are having a 













市售的丹參化學物中，隱丹參酮和二氫丹參酮之半數抑制量(ICsQ)分別是5|iM a n d 
0.5nMo 丁醯膽鹼脂酶亦名假乙醯膽驗脂酶，它跟乙醯膽驗脂酶在結構上十分 
相似。硏究發現隱丹參酮和二氫丹參酮對乙醯膽驗脂酶有很高的專一性。 
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CHAPTER 1 GENERAL INTRODUCTION 
Neurodegenerative diseases are neurological disorders including Alzheimer's disease 
(AD), Parkinson's disease and Pick's disease and are marked by the gradual loss of 
nerve cells. The complex disease mechanisms and difficulties of earlier diagnosis are 
the two main factors that make these diseases devastating. Neurodegenerative diseases 
are likely caused by different etiology although it has been suggested they share similar 
pathogenic mechanisms (Hardy, 2001). Not until we can have a complete 
understanding of the causes of diseases, the development of drugs that can ease the 
symptoms and slow down its progression may also be extremely important. 
1.1 Alzheimer's Disease 
According to the definition of the Alzheimer's Disease Association, AD is a progressive, 
neurodegenerative disease characterized by loss of function and death of nerve cells in 
several areas of the brain, leading to loss of mental functions such as memory and 
learning. Alzheimer's disease is the most common cause of dementia. AD was named 
after Dr. Alois Alzheimer, a German physician who first documented the clinical 
symptoms of this disease in 1906. AD is now a major cause of non-vascular dementia 
in the ageing population, affecting 10% and 50% in people over the ages of 65 and 85 
respectively. It is estimated that the number of AD patients in the US will rise to 14 
1 
million in 2050 due to the aging population (Long & Dougherty, 2003). 
Dementia is characterized by a decline in cognitive performance that is severe enough 
to disrupt patients' ability for routine tasks. Decline in cognition will usually 
accompany with a progressive loss in memory (especially the short-term memory), 
language skills, spatial skills, abstraction, calculation and judgment while delusions, 
hallucinations, depression, mania and anxiety are some other extensions (Green, 2002). 
There are two common causes of dementia, the vascular dementia due to 
cerebrovascular arteriosclerosis or ischemic brain damages and the dementia due to the 
progression of AD (ladecola et al, 2003). Dementia is a burden to the health care 
system and to the patients' family. Treatment approaches in AD are based on improving 
cognitive function only. At present, there is still no cure for AD. 
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1.2 Hallmarks of AD 
Senile plaques, neurofibrillary tangle (NFT) and the loss of cholinergic neurons are the 
three major hallmarks in AD (Perry et al, 1998, Mudher & Lovestone, 2002). 
1.2.1 The amyloid cascade hypothesis 
The composition of senile plaques was first characterized to contain excess of 40-42 
amino acid peptides called the P-amyloid (Ap) (Selkoe, 1993). The amyloid cascade 
hypothesis states that AD is caused by an aggregation of amyloid plaques composed of 
Ap peptide 1-42 in the affected region of the brain. The accumulation of senile 
plaques eventually kills the neurons surrounding the plaques. These amyloid peptides 
were later known to be derived from a larger membrane bound protein called the 
amyloid precursor protein (APP) by selective proteolytic cleavages by at least two 
proteases, a-Secretase and p-amyloid cleaving enzyme (BACE). Cleavage by 
a-secretase gives the non-amyloidogenic fragment Api-40 while cleavage by BACE 
followed by Y - secretase/presenilin cleavage give rise to the amyloidogenic 
Api-42(43)fragment. This peptide is more susceptible to self-aggregation and its 
aggregation is thought to be the major cause of toxicity and result in the neuronal cell 
death of AD patients (Mudher et al 2002). 
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Fig. 1.1 Amyloid cascade hypothesis (Mudher & Lovestone�2002) 
1.2.2 The tauopathy hypothesis 
NFT is mainly composed of paired-helical filament (PHF) and PHF itself is formed by 
the polymerization of hyper-phosphorylated tau protein. Tau is a neuronal-specific 
microtubule-binding protein that helps to stabilize the microtubule. Microtubule is 
important for the transport of nutrients in the cell (Burkhart et al, 1998) and it is 
replaced by tangles in disease neurons (Augustinack et al, 2002). In the tau and tangle 
hypothesis, some believe that hyperphosphorylation of tau reduces its binding capability 
4 
to the microtubule, resulting in microtubule stabilization problem in neuronal cell. And 
that the phosphorylation of tau is the critical process that leads to neuronal cell death. 
However, since phosophorylation of tau occurs after free tau aggregation, some believes 
that it is the aggregation that causes the tau protein not functioning and eventually leads 
to neuronal cell death. 
Several kinases are important to the tauopathy, like the glycogen synthase kinase-3 
(GSK-3), mitogen-activated protein (MAP) kinase and the cyclin dependent kinase-5 
(Cdk-5). The action of GSK-3 on tau phosphorylation has been well studied (Sperber et 
al, 1995). It ha also been reported that GSK-3a and/or GSK-3p, rather than MAP kinase 
are good candidates for generating PHF-type phosphorylation of tau in Alzheimer's 
disease (Lovestone et al, 1994). Recently the importance of Cdk-5 in tau and tangle 
formation has also been illustrated. Mice over-expressed with cdk5 activator p25 were 
crossed with mice over-expressed with mutant human tau. The crossed mice showed 
no change in level but increased in activity of Cdk5. Increase in the amount of insoluble, 
hyperphosphorylated aggregated tau was also observed (Noble et al, 2003) 
5 
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Fig. 1.2 The tauopathy hypothesis (Mudher & Lovestone, 2002) 
1.3 The Cholinergic Hypothesis 
Cholinergic hypothesis states that the learning and memory deficits of dementia in the 
aged and in AD may be attributed by the decline in the cholinergic systems of the basal 
forebrain. Impairment of such system results in the decline of acetylcholine level and 
the cognitive impairment observed in dementia. This hypothesis is not considered as an 
early event in AD since the cholineacyltransferase activity, remains normal in patients 
with mild AD at death (Tiraboschi et al, 2000). 
6 
At present, the only FDA approved drug for treating AD is based on its 
acetylcholinestease (AChE) inhibitory activities, thereby restoring the acetylcholine 
level at the synapses. Synthesis of acetylcholine is by acetyl-CoA and choline with 
enzyme choline acetyltransferase (ChAT) as a catalyst in the cytoplasm of cholinergic 
neurons. Acetylcholine is an important neurotransmitter that is highly related to 
cognitive behavior and memory (Fadda et al, 1996 & 2000). It is released through the 
stimulation of vagus nerve and is the first neurotransmitter discovered which plays a 
significant role in synaptic transmission (Bohln et al, 2002). The released ACh 
molecules travel through the synaptic cleft and reaches the postsynaptic terminal where 
they meet receptors docked on the surface. Different effects will be determined by the 
type of receptor they come across. ACh acts as a neurotransmitter when it interacts 
with two main classes of receptors: muscarinic and nicotinic receptors. 
1.3.1 Cholinergic drug therapy 
Anti-cholinesterase drugs can eliminate dementia-like symptoms induced by 
antimuscarinic drugs like scopolamine in both human and animals, and exocytoxic 
lesions in the nucleus basalis can be partially reversed by cholinesterase inhibition 
(Stone, 1994). Restoring the ACh level in the ACh depleted AD brain can help to 
slower down the disease progression (Zwart et al, 2000, Fisher 2000, Reichman et al, 
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2003). Various methods in restoring ACh have been investigated. There are generally 
three approaches to increase ACh level in the brain: (1) use precursors, like choline to 
boost the ACh synthesis, (2) use anticholinesterase drugs to lower the degradation of 
ACh and (3) use specific agonists to replace the action of ACh on the corresponding 
nicotinic and muscarinic receptors (Stone 1994). However, the precursor approach with 
choline or lecithin has been shown to be ineffective (Bartus et al, 1982) as no 
observable change in acetylcholine level was found after their intake. 
1.3.2 Acetylcholinesterase inhibitors 
Acetylcholinesterase (AChE) is responsible for the degradation of ACh in the neuronal 
synapses. There are two important esterases in the ACh metabolism - the 
acetylcholine esterase (AChE) and butyrylcholine esterase (BuChE) or 
pseudocholinesterase. AChE has a molecular mass of 80kDa and occurs in the globular 
monomeric form (Gl), dimeric (G2) and tetrameric (G4) form and the asymmetric 
A4,A8 and A12 collagen-tailed form. 
G4 form is the major form in most region of the mammalian brain (Marsh et al, 1984， 
Skau et al, 1999), while the monomeric Gl form is present only in small amount. 
Different AChE inhibitors inhibit these forms with preference. Equal inhibition 
8 
preference is observed in physostigmine, while rivastigmine prefers to inhibit G1 form. 
The selective inhibition of different AChE inhibitors in different form of AChE and their 
region specific inhibition indicate the importance of choosing the most appropriate 
inhibitors for treatment (Zhao et al, 2002). 
Dementia is the most prominent symptom in Alzheimer's disease. Cerebral cortex and 
hippocampus are regions that regulate the cognitive performanc and the losses of 
cholinergic synaptic inputs in these areas are the cause of symptoms in Alzheimer's 
disease. This indicates the importance of restoring the acetylcholine level in regions 
like the basal forebrain area. It is equally important to target on region that is rich in 
AChE, such as the striatum (Kawaguchi et al, 1995). The type of inhibition caused by 
acetylcholinesterase can be present in several forms, either by directly binding to the 
active center gorge or to the allosteric modulating sites. Donepezil (Aricept™), 
ENA-713 (Exelon™), Galantamine (Reminyl™) and Tacrine (Cognex™) are the 
cholinesterase inhibitors approved by the US Food and Drug Administration (FDA) in 
treating AD. The drugs are usually accompanied with side-effects such as vomiting, 
dizziness and gastrointestinal discomfort and also problems in the development of drug 
tolerance after long-term intake. However, in a suitable therapeutic dose, patients 




Tacrine (THA) belongs to the first generation of AChE inhibitor and it is the first FDA 
approved drug for treating AD. However, it was later discovered to elevate level of 
alanine aminotransferase and results in hepatotoxicity at a dose over 80 mg per day 
(Holford et al, 1992, Roberts et al, 1998). Although the action of tacrine is reversible, 
it is not specific enough and inhibits BuChE more than that of AChE. Recent study 
shows that tacrine also acts as a muscarinic receptor antagonist of rat duodenum Ml and 
M3 subtypes and induces the release of ACh in rat cortical synaptosomes through the 
interaction Ml subtypes and M2 subtypes. This indicates that the drug not only acts as 
acetylcholinesterase inhibitors, but also causes blockage of muscarinic receptors and 
results in the observed gastrointestinal symptoms (Svensson et al, 1996’ Becerra et al, 
2001). 
1.3.2.2 Donepezil 
Donepezil hydrochloride (E2020) is a potent selective cholinesterase inhibitor that has 
been approved in 1996 by the FDA and shown to improve cognitive performance and 
daily routine tasks with mild to moderate AD. Donepezil has a N-benzylpiperidine 
10 
and an indanone moiety and with this structure, it is more selective over AChE with an 
in vitro IC50 at 5.7 ± 0.2 nM over rat brain AChE and 7138nM 土 1.33 nM over rat 
plasma BuChE. Its duration in the blood is also longer than that of tacrine (Sugimoto 
et al, 2001 & 2002). The discovery of donepezil is by random screening of 
compounds that are originally synthesis for treating arterial sclerosis (Sugimoto et al, 
2001). It is a well-tolerated drug that shows no hepatotoxicity after 144 weeks trial 
(Rogers & Friedhoff’ 1998,Kosasa et al, 2000, Rogers et al, 2000). Recent data show 
beneficial dose of donepezil should be 5 to lOmg daily (Wilkinson, 1999). Currently 
donepezil is marketed in 56 countries under the trade name Aricept®. 
NH2 P 
r r V ^ C H 3 � y y ^ … ‘ hcl 
Tacrine Donepezil (E2020) 
(Cheng et al, 1996) 
Fig. 1.3 Structures of tacrine and donepezil 
1.3.2.3 Rivastigimine - ENA-713 
Rivastigmine is also named as ENA-713. It has a longer action than tacrine and 
donepezil and it is also found to elicit the least peripheral cholinergic effects that are 11 
common in other cholinesterase inhibitors. It is approved for the treatment of mild to 
moderate AD. Benefits of rivastigmine over tacrine include that it does not metabolize 
in the liver and produces toxic metabolite like tacrine. Only phenolic cleavage product 
is observed in the body of animal and human after rivastigmine intake (Sramek et al, 
1996, Habucky et al, 1998). Therapeutic dose of rivastigmine is 6-12mg/day (Sramek 
et al, 1996，Desai and Grossberg, 2001, Rosier,2001). Very different from that of 
tacrine and donepezil, rivastigmine is called the "pseudo-irreversible" agent as it can 
give an AChE inhibition up to 10 hours, while the effect of tacrine and donepezil AChE 
only takes place when the drugs are being taken (Desai and Grossberg, 2001). 
H a C N(af3>2 
Rivastigmine (ENA-713) (Habucky et al, 1998) 
Fig. 1.4 Structure of Rivastigmine 
1.4 AChE inhibitors from plants 
1.4.1 Galanthamine 
Galanthamine (or galanthamine, Reminyl®) is a tertiary alkaloid acetylcholinesterase 
12 
inhibitor. It is approved by the FDA with trade name Reminyl® to treat mild to 
moderate AD. It is a long action, selective and reversible AChE. Galanthamine is 
derived from the bulbs of common snowdrop and several members of the 
Amaryllidaceae family. It has long been used for neuromuscular paralysis and its 
usage as AChE inhibitor is known 5 years after (Harvey et al, 1995). The specialty of 
galanthamine over other AChE inhibitors is that it can not only inhibit the 
acetylcholinesterase from degrading acetycholine with moderate specificity, it can also 
act as an allosterically potentiating ligand (APL) stimulating the acetylcholine 
production in the neuronal synapses. 
Using nicotinic agonist is a possible approach to up-rise the level of synaptic ACh in 
AD patients. However, there is always problem in the dosage of using such agonists 
because high dose level will result in desensitization rather that increased activation of 
nicotinic receptors (WoodrufF-Pak et al, 2001). Galanthamine, as an APL, exert its 
effect on nAChR by binding to a site distinct to the active site. Since it does not 
directly bind to the active site, its effect will not be compensated by that of nicotine 
which results in desensitization. The fact that galanthamine does not compete or exert 
a stimulation by itself over nAChR further prove its role as an APL (Zwart, 1997& 
2002). The specificity of galanthamine on nAChR but not mAChR is also reported in 
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CHO cell expressed with mAChR (Samochocki et al, 2003). 
With the success of galanthamine, alkaloidal compounds screened and isolated from 
various Narcissus species were also shown to have AChE inhibitory activities (Lopez et 
al, 2002，Ingkaninan et al, 2000, Rhee et al, 2001). Most of them retain the skeleton of 
galanthamine and lycorine. The compound sanguinine that has galanthamine like 
structure has an IC50 at 0.1 |jM, even shown to have stronger inhibitory effect than 
galanthamine (i.e. IC50 = LOTjiM) (Lopez et al, 2002). However, whether it can act as 
an APL is not yet known. 
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Fig. 1.5 Structures of galanthamine and sanguinine 
1.4.2 Huperzine 
Huperzine A, a new Lycopodium alkaloid, is isolated from the Chinese herb Huperzia 
serrata (Thunb.) Trev. It is a selective AChE inhibitor and can improve spatial 
memory deficit induced by scopolamine in the radial maze task. The effect is more 
14 
significant in oral administration (Cheng et al, 1996). Huperzine A preferentially 
inhibits G4 form tetrameric acetylcholinesterase (Zhao et al, 2002)，the most common 
form of AChE present in mammalian brain (Marsh et al, 1984, Skau et al, 1999). It 
has been proposed to protect AChE from nerve agent toxicity i.e. the organophosphate 
poisoning-induced phosphorylation. Also, pretreatment of neuronal culture with 
huperzine A can inhibit the NMDA induced toxicity in a dose dependent manner 
(Gordon et al, 2001). Huperzine A not only can act as an effective acetylcholinesterase 
inhibitor, it also shows to reduce the neuronal degeneration induced by beta-amyloid 
protein-(l-40) (Wang et al, 2001). 
CHj 
V mi 
Huperzine A (Cheng et al, 1996) 
Fig. 1.6 Structure of huperzine A 
1.4.3 a-onocerin 
Triterpenoid a-onocerin is extracted from another plant, L. clavatum, (Orhan et al, 
2003). Among the 5 screened chloroform: methanol ( 1 : 1 ) extracts of Lycopodium 
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species, namely L clavatum L., L selago L.，L annotinum L., L alpinum L., and L. 
complanatum ssp. chamaecyparissus A. (Br.) Doll., only extract from L. clavatum can 
give an in vitro IC50 at 5.2|jM. 
H3C. r 
r I 
CH3 J CH^ 
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H a C r � C H 3 
a-onocerin (Orhan et al, 2003) 
Fig. 1.7 Structure of a-onocerin 
1.4.4 (+)-a 丨 pha-viniferin 
Methanolic extract of underground parts of Caragana chamlague (Leguminosae) was 
found to have an inhibitory effect on AChE. Underground part of Caragana 
chamlague is traditionally used to treat neuralgia, rheumatism, arthritis in Korea and 
China. Subsequent extraction yielded the compound (+)-alpha-viniferin to inhibit AChE 
with IC50 at 2 |iM. This compound is found to have specific, reversible and 
non-competitive action towards AChE inhibition (Sung et al, 2002). 
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1.5 My project 
Success of galanthamine as an AChE inhibitors and APL of nAChR and the existence of 
many other AChE inhibitors from plants suggest that it is beneficial to screen herbs for 
treating neuronal diseases. I have therefore taken the advantage of the existence of 
well-document literatures in using Chinese medicine to treat neuronal disorders. 
Frequently used herbs are screened and active components are investigated for the 
inhibition of acetylcholinesterase activity. The objective of this project is to screen for 
AChE inhibitors from Chinese medicinal materials. 
17 
CHAPTER 2 MATERIALS AND METHODS 
2.1 Preparation of CMM 
2.2.1 Selecting criteria and sources 
A total of 50 Chinese medicinal materials (CMM) were selected by their highest 
occurring frequency in the 1500 formulations published "Chang Jian Nao Bing Liang 
Fang 1500 Shou"(常見腦病良方一百五十首）for treating dementia. Herbs were 
purchased from the Tongrentang Hong Kong Ltd. 
2.2.2 Preparation of aqueous extract 
10 gram of CMM was boiled in 80ml of distilled water under reflux for 45 minutes. The 
boiling extract was then filtered and the clear filtrate was then lyophilized. The powdery 
lyophilized material was weighed. 
2.2.3 Preparation of ethanol extract 
10 gram of CMM was soaked twice, each for an overnight in 50 ml of absolute ethanol. 
A total of lOOmL extract was then cleared by filtration on a 3M paper and then 
lyophilized. The sticky jelly like lyophilized material was weighed. 
18 
2.3 Routine maintenance of cell lines 
Human neuroblastoma SH-SY5Y cells were cultured with Dulbecco's modified Eagle's 
media (DMEM/F12) supplemented with 10% fetal bovine serum, 1% L-glutamine and 
1% penicillin-streptomycin in 100mmx20mm cell culture dish until confluent. All cells 
were incubated under 5% CO2 at 37°C. 
Mouse neuroblastoma NlE-115 cells were cultured with Dulbecco's modified Eagle's 
media supplemented with 10% fetal bovine serum and 1% of penicillin-streptomycin in 
100mmx20mm cell culture dish until confluent. The culturing reagents were obtained 
from Gibco. 
2.4 Toxicity test 
MTT assay was used to check for the toxicity of the selected primary hAChE inhibitors. 
Only metabolic active cells can cleave the tetrazolium salt MTT and form a formazen 
dye. 10,000 cells per well were seeded in a 96 well plate and incubated overnight. 
The serum-containing medium was changed with herb extracts or drugs containing 
serum-free medium the next day. After 24 hours incubation, the serum free medium 
was removed and 50|iL Smg/mL MTT powder 
(3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetraxolium bromide) (Sigma, M-2128) 
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diluted to Smg/mL in distilled water was added. Dimethyl sulfoxide (DMSO) (Sigma, 
D-8418) was added to release the tetrazolium salt formed. The O.D. measured at 
412nm was directly proportional to the number of viable cells. The DMSO 
concentration was kept below 0.01% to avoid cytotoxicity induced by DMSO. 
2.5 Ellman assay 
The screening for cholinesterease inhibitors by the method of Ellman assay was used 
(Ellman et al, 1961). Human acetylcholinesterase (hAChE) in buffer was added to the 
test chemicals/CMM extracts followed by the addition of acetylthiocholine (ATCI) 
substrates and Ellman's reagent - 5'5-dithio-bis-(2-nitrobenzoate) (DTNB). The AChE 
inhibitory activity was monitored by the release of thiocholine that was then reacted 
with DTNB to form a bright yellow product. The optical density of the color product 
at 415 nm was spectrophotometrically determined. 
Ellman assay was performed on a 96 well-plate as follows: a predetermined amount of 
aqueous or ethanol extract (as described above) in assay buffer (lOOmM sodium 
phosphate buffer, pH 7.4) was mixed with 0. limit of hAChE (Sigma, C-1682). After a 
short pre-incubation (i.e. 10 minutes), equal amount of 12.5mM of Acetylthiocholine 
iodide (ATCI) (Sigma, A-5751) was mixed with lOmM 5'5-dithio-bis-(2-nitrobenzoate) 
20 
DTNB (Sigma, D-8130) and the mixture was added to a well. After 10 minutes, the 
optical densities were measured in a 96-well plate reader at 415 nm within 5-8minutes. 
Optical density was inversely proportional to the inhibitory activity. 
2.6 Ellman assay over BuChE 
The specificity of the selected active components over AChE was also tested. Ellman 
assay was employed except; butyrylcholinesterase (Sigma, C-9971) was used instead of 
acetylcholinesterase. Only cryptotanshinone, dihydrotanshinone I and galanthamine 
were examined. 10-fold dilution was made with highest concentration at 40jjM or 
80|aM, depending on solubility. 
2.7 Drugs 
The anti-cholinesterase activities of selected active components of Salvia miltiorrhiza 
were also tested with Ellman assay. They are protocatechualdehyde (MW= 138.12), 
tanshinone IIA (MW= 294), tanshinone I (MW= 276), cryptotanshinone (MW=296), 
salvianic acid B (MW= 718) and dihydrotanshinone I (MW=278). All of them were 
obtained from the National Institute for the Control of Pharmaceutical and Biological 
Products, State Drug Administration, PR. China (中國药品生物制品檢定所). 
Galanthamine Hydrobromide (MW= 368.3) was purchased from Calbiochem 
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(Calbiochem® 345670). 10-fold dilution was made with highest concentration at 40jaM 
or 80pM. 
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CHAPTER 3 SCREENING OF ACETYLCHOLINESTERASE INHIBITORS 
FROM CHINESE MEDICINAL MATERIALS 
3.1 Introduction 
The book "Chang Jian Nao Bing Liang Fang 1500 Shou"(腦病良方一百五十首） 
contains 500 Chinese medicinal formulations for treating brain diseases. Within these 
500 formulations, 45 herbs with their highest occurring frequency were selected for 
screening of acetylcholinesterase inhibitory activities. 
3.2 Materials and Methods 
Both aqueous and ethanol extracts of 45 CMMs were tested for inhibition of 
acetylcholinesterase activity by the Ellman assay. The CMM extracts were prepared as 
described in 2.2.2 and 2.2.3 Chapter 2. Preliminary screening was performed with 
50|^g/inL of CMM extracts. 6 CMMs with anti-cholinesterase property in both 
aqueous and ethanol extracts were re-screened. Data analysis was performed with 
Sigma Plot 2001 software in the re-screening process. Inhibitory effects in response to 
the CMMs were presented as the percentage inhibition. The screening experiments were 
repeated at least twice. For CMMs that were shown to have significant inhibition, 
dose-dependent inhibitory assays were also performed. 
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3.3 Results and discussion 
3.3.1 Preliminary screening of 45 selected CCMs for AChE inhibition 
Percentage inhibition (%) 
Herbs screened Aqueous Ethanol 
黨參 6.540698 26.30814 
甘草 5.741279 8.648256 
半夏 4.796512 9.738372 
赤苟 77.5436 65.9157 
一 黑芝麻 -4.49438 一 7.173725 
紅花 -13.3967 2.333621 
生地 -0.43215 23.76837 
58.5134 78.73812 
炒棗仁 -22.299 7.087295 
— 麵 0 1.642178 
陳皮 -7.60588 -6.13656 
丹參 46.06742 72.1694 
^ 6.309421 51.33967 
S S 0.432152 -7.26016 
33.62143 56.43907 
山叟肉 45.45455 29.54545 
白术 -2.09091 -6.54545 
一 川牛膝 -3 一 1.545455 
僵蚕 -30.9091 17-54545 
膽星 -3.54545 -0.54545 
勾藤 55.22814 19.58175 
^ 27.09125 40.20913 
一 冤絲子 -10.076 — 1.330798 
郁金 -5.60837 ^ 
伏爷 -18.0608 9.980989 
巴戟 3.810409 -2.41636 
石昌蒲 -6.04089 55.76208 
^ 24.44238 -30.2045 
五味子 1.486989 5.762082 
— 大黃 80.97295 75.26053 
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杞子 -14.9628 -3.25279 
黃民 -12.936 -9.15698 
首烏 59.88372 47.23837 
田七 -38.0814 -53.1977 
靈芝 -8.57558 33.86628 
葛根 -5.52326 -1.74419 
雞血藤 77.74194 64.67742 
蟲草 -74.0323 14.03226 
黃精 ^ -22.9032 
女貞子 -17.5806 24.51613 
^ -19.8387 -60.3226 
益 21.2976 4.93653 
桃仁 -2.11566 ^ 
jTi^ -14.1044 n ^ 
d j ^ 7.616361 20.73343 
— 紅參 -15.9379 -31.5938 
Table 3.1 Effects of selected CMMs on inhibition of acetylcholinesterase activity. 
The aqueous and ethanol extracts at 50 |^g/ml were tested in the Ellman assay. 
Percentage inhibitions were calculated as compared to DMSO control. 
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3.3.2 Rescreening of drugs that show AChE inhibition in both aqueous and organic 
extracts 
BaiShao He ShouWu 
0 10 30 90 60 t o o control 10 20 SO SO 100 
c o n c t n l r a l l o n ( ^ g / m L ) c o n c e n t r a l o n t j i Q / m L ) 
Chi Shao Ji Xue Teng 
100 100 
J i - ^ ' 80. ^ 1 1 
JR I iiy\ 
7 " ；T T ； I ^ ^ control 10 20 50 80 100 cont ro l 10 20 5 0 80 100 
c o n c . n l r . t l o n (msMiL) c o n c e n t r a t i o n ( n g M i L ) 
Da Huang Danshen 
100 1 
100 
con t ro l 10 20 50 80 100 I , , , , _ • _ 
c o n « n l r•丨 I o n O i f l / m L ) 0 2 0 4 0 6 0 BO 1 0 0 1 2 0 
concentra t ion C^g/mL) 
Fig. 3.1 Acetylcholinesterase activity on the six selected CCMs. Both aqueous 
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and ethanol extracts of CCMs with the indicated concentrations were used. Open 
circle indicates ethanol extracts while solid circle indicates aqueous extracts. Bars 
indicate mean 土 SEM of n=3. 
Aqueous extract Ethanol extract 
I C 5 0 (lag/mL) 
Bai Shao 20 8 
Chi Shao 14 45 
Da Huang 32 18 
He Shou Wu 13 65 
Ji Xue Teng 85 9 
Danshen 50 5 
Table 3.2 IC50 of both extracts of the six selected herbs. 
During the preliminary screening there are herbs that exert an inhibitory effect over 
hAChE in both extracts and herbs that gave the same effect in either one of the extract. 
In the experiment, only herbs that gave a positive and high enough inhibition over 
hAChE in the preliminary test were re-screened. With this criteria only six herbs were 
re-screened from the original 45 herbs and dose dependent inhibitory responses were 
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observed. 
Among the re-screened herbs, all extracts showed an inhibitory effect on hAChE. As 
seen from Table 3.2, ethanol extracts gave a higher inhibition than the aqueous one. 
However, inhibitory effect was observed to be stronger in the aqueous extracts of Chi 
Shao and He Shou Wu. The IC50 for the aqueous extract of Chi Shao and He Shou Wu 
were 14 and 13 |j,g/mL respectively. The IC50 for the ethanol extracts of Bai Shao and Ji 
Xue Teng were around 8 |ig/mL while the IC50 of Da Huang was around 18[ig/mL IC50 
for Danshen was only 3 |j,g/mL. 
3.4 Discussion 
Bai Shao (白苟）and Chi Shao (赤苟） 
Bai Shao is the root of Paeonia lactiflora Pall, and Chi Shao is the root of Paeonia 
lactiflora Pall, P. veitchii Lynch or several other species of the same genus. Both of 
them belong to the family Ranunculaceae. 
Active ingredients in Bai Shao contain paeoniflorin, paeonin, albiflorin, benzoic acid, 
P-sitosterol, gallotannin, volatile oils, resin, starch, proteins and triterpenes. 




ingredients in Chi Shao include paeoniflorin, albiflorin, oxypaeoniflorin, 
benzoylpaeoniflorin, lactiflorin and benzoic acid, d-catechin and gallic acid have also 
been found in this herb. Both Bai Shao and Chi Shao can relieve pain. The action of 
Bai Shao is for nourishing the Blood, constrain Yin and calm the Liver to relieve pain 
while Chi Shao tends to relieve the pain by clearing heat, quicken the Blood and 
dissipate stasis. 
Da Huang (大黃) 
Da Huang is the root and rhizome of Rheum palmatum L., R.Officinale Baill, or 
RJanguticum Maxim, ex Balf. (Huang, 1999) of family Polygonaceae with common 
name as Chinese rhubarb. (Xu & Wang, 2002). Major components of Da Huang 
contains Cinnamic acid, gallic acid, anthraquinone compounds, calcium exalate, 
glycosides, rhein-8-monoglucoside, physcion monoglucoside, aloe-emodin 
monoglucoside, chrysophenol monoglucoside, sennoside A, B, and C. Rheum tannic 
acid and catechin. 
HO O OH 
^ 0 
R = Rl= 
Rhein COOH H 
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Emodin OH CHS 
Chrysophenol CHS H 
Aloeemodin CH20H H 
physcion 0CH3 CHS 
Fig. 3.2 Structure of active components from Da Huang. 
The hydrolyzed products of the glucosides emodin and sennnidin are the active 
components that cause the laxative effect of Da Huang. 
He Shou Wu (何首烏） 
He Shou Wu is the root tuber of Polygonum multiflorum Thunb, a plant in the family 
Polygonaceae. It contains anthraquinone derivatives like chrysophanol and emodin, as 
well as rhein, physcion, questin, lecithin, P-sitosterol, glycoside - rhaphantin, 
polygonimitin B ’polygonimitin C and starch. This herb can lower plasma cholesterol 
level by reducing the absorption of dietary cholesterol. Lecithin is suggested to block 
cholesterol uptake and avoids them from deposit in the arterial wall. Generally it is 
non-toxic in nature regardless of the common adverse effect like nausea or vomiting 
that may due to the presence of emodin. 
JiXueTeng (雞血藤） 
Ji Xue Teng is the dried stem of Spatholobus suberectus Dunn, of family Leguminosae. 
Major components include formonetin, ononin, prunetin, daidzein, afromosin, 
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licochalcone A, 2,4,3,4-tetrahydroxychalcone, protocatechuic acid, P-sitosterol, 
daucosterol, campesterol, stigmasterol and milletol. Not much study has been done on 
the clinical use of Ji Xue Teng. 
Danshen (丹參） 
Dan Shen is the root and rhizome of Salvia miltiorrhiza Bge. of family Labiatae. Active 
ingredients of Dan Shen include tanshinone I, HA, IIB, cryptotanshinone, miltirone, 
tanshinol I and 11, nortanshinone, tanshilactone, salviol, protocatechuic acid, 
protocatechuic aldehyde, baicalin, ursolic acid, daucosterol and vitamin E. Detail of 
the usage of Dan shen will be discussed in Chapter 4. 
The six herbs selected show the highest inhibition of acetylcholinesterase in their 
ethanol extract except Chi Shao and He Shou Wu that are more potent in the aqueous 
extracts. This is not difficult to understand as many plant alkaloids, that are mostly 
hydrophobic in nature, are believed to be potential inhibitors for varies enzymes. 
(Cordell et al, 2002). It is worth to screen for hydrophobic compounds for Alzheimer's 
disease therapy as their properties aid transportation to brain. The presence of blood 
brain barrier (BBB) makes it difficult for hydrophilic compounds to reach the brain 
region and exert its action. Most of the neuronal drugs like the caffeine and morphine 
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are hydrophobic in nature, 
O 
16—NH HgC^ M 广 7 
\ z \ 10——9 H N � / \ / 1 — — 1 1 15 1 4 — 8 
八 Z——N II \ \ V \ 
3 = ^ 4 5 6 CH3 \ 
CH3 
Caffeine Morphinan 
Fig. 3.3 Structure of caffeine and morphinan 
At 100|ag/mL, both aqueous and ethanol extracts of Da Huang had 80% inhibition over 
hAChE, indicating that there may be more than one inhibitors in the herb, or the 
compound is amphiphatic. 
In the case for Danshen and Ji Xue Teng, a very distinct difference between inhibition in 
aqueous and ethanol extracts were observed. (Fig.3.1). The highest inhibition given by 
Danshen and Ji Xue Teng ethanol extract were 90% and 80% respectively. Further 
analysis on the active components of Danshen on acetylcholinesterase inhibition was 
carried out because Danshen is a well-studied herb with active components readily 
available. 
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CHAPTER 4 CHARACTERIZATION OF 
ANTI-ACETYLCHOLINESTERASE ACTIVITY FROM SALVIA 
MILTIORRHIZA BGE.(丹參） 
4.1 Introduction 
Danshen (丹參)is the dry root of Salvia miltiorrhiza Bge. It is a native plant in China. 
It has been recorded in many Chinese medicinal prescriptions. In the prescription 
"Tianwang Buxin Dan"(天皇保心、丹)that is mainly used to treat insomnia, mental 
agitation and memory problems, the function of Danshen is primarily for "heart 
nourishing and spirit pacifying action" (Dharmananda, 2002). In modem Chinese 
medicine, Danshen is recognized as a useful blood-vitalizing agent. Salvia 
miltiorrhiza is able to increase coronary flow and reduce coronary resistance, and to 
produce vasodilation action. It also possesses anti-platelet aggregation and sedative 
effect (廣東中醫學院，1976’ Tang et al, 1992). Danshen is also recommended for 
prevention of liver damage due to viral hepatitis and fibrosis of liver. Due to the 
blood vitalizing property, Danshen is also used for the treatment of menstrual disorder, 
menostasis and menonrhalgia (Dharmananda, 2002, Tang et al, 1992). 
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4.1.1 Clinical application of Danshen 
The injection of Danshen aqueous extract increases the flow rate in the aorta and the 
circumflex branch of the left coronary artery. Danshen also improves the clinical 
symptoms of acute myocardial ischemia induced by pituitrin in rabbits and rats (Yang 
et al, 1979). Danshen can increase the coronary flow rate and shown to have a 
protective effect on heart against ischemia and reperfiision. (Zhou et al, 1990). 
Danshen has recently been shown to attenuate intimal thickening in the 
balloon-injured abdominal aorta of cholesterol-fed rabbits (Chen, et al, 2001). 
4.1.2 Pharmacological properties of Danshen and Salvia species 
Not only is the herb Danshen, but also the whole Salvia genus has attracted the 
attention of scientists,. In fact, in western folk medicine, the Salvia genus has been 
collectively named as Sage and it is used in antitranspirant, anti-inflammatory, 
antibacterial and antiviral preparations. Anti-inflammatory, antibacterial, antioxidative 
and neuroprotective properties of Sage have also been scientifically proved (Lam et al, 
2003, Lee et al, 1999，Kim et al, 2002). Some focus on active components extracted 
from sage, while others use the crude extracts of sage (either aqueous or lypophilic 
extract) to test with available animal models. 
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4.1.2.1. Anti-inflammatory and antibacterial responses 
Tanshinone I isolated from Danshen was reported to interfere with in vivo 
anti-inflammatory response by acting as phospholipase A2 inhibitor (Kim et al, 2002). 
Crytotanshinone and dihydrotanshinone I exert antibacterial activities by acting as 
active oxygen radical generators (Lee et al, 1999). 
4.1.2.2 Diabetes 
The polyol pathway that can be found in the lens retina, nerve and kidney where 
diabetic complication appears are tightly linked to the enzyme aldos reductase. It is 
found that aldos reductase can be inhibited by danshenol A, danshenol B, 
dihydrotanshinone I，cryptotanshinone, tanshinone I and sugiol (Tezuka et al, 1997). 
4.1.2.3 Alcoholism 
A recent interesting discovery is the use of Danshen as a potential drug to combat 
alchoholism. Injection of lypophilic extract of Danshen to alcohol-preferring rats 
lowers their acquisition for alcohol drinking (Brunetti et al, 2002, Vacca et al, 2003). 
This is the first evidence that Danshen can actually affect the behavior of mammals. 
35 
4.1.2.4 Apoptosis 
Danshen extract is found to induce programme cell death in HL60 human 
premyelocytic leukemia cell line (Yoon et al, 1999) and one of the responsible 
chemicals is believed to be Tanshinone IIA. A characteristic of apoptosis is the 
proteolytic cleavage of PARP, an enzyme involves in DNA repair. Tanshinone IIA 
was found to induce such cleavage in HL60 and an increasing capase-3 activity was 
also observed. In hepatic fibrosis, it is believed that apoptosis of the hepatic stellate 
cells may be a primary mechanism to avoid its further development into fibrosis. 
Recently, tanshinone I was also found to induce apoptosis in rat hepatic stellate cells 
transformed by simian virus (SV40). The apoptotic action is more or less similar to 
that of tanshinone IIA in the HL60 case, which is through the activation of capase-3 
and promoting the cleavage of PARP (Kim et al, 2003). 
4.1.2.5 The effect of Salvia extracts on neuro-receptors 
The effect oi Salvia species on muscarinic and nicotinic acetylcholine receptors in the 
central nervous system has also been recorded (Wake et al, 2000). Ethanol extracts 
of Salvia species can displace choline or scopolamine in extracted human brain 
membrane. Although their displacement activities vary from species to species and 
the active components that are responsible for such dose-dependent displacement 
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have not yet been elucidated, these observations have already provided the potential 
for further investigation of the possible active ingredients. 
Camosic acid, camosol, 7-Methoxyrosmanol and galdosol extracted from Salvia 
officinalis may act as ligands for human brain benzodiazepine receptor (Kawadias et 
al, 2002). Benzodiazepines receptor is a kind of GAB A receptors and once stimulated 
by benzodiazepines, can potentiate the chloride ion conductance induced by GAB A or 
membrane hyperpolarization and modulate anxiety. 
Recently, tanshinone is found to exert neuroprotection in transient focal cerebral 
ischemia mice, there is observable absence of neurological deficit for mice 
intraperitoneal with tanshinone IIA. It has also been found that tanshinone IIA can 
pass through the blood brain barrier as a considerable amount of tanshinone IIA can 
be detected in the brain after injection (Lam et al, 2003). 
4.1.3 Anti-cholinesterase activity by the Salvia species 
The anti-cholinesterase activity oi Salvia Lavandulaefolia was recently demonstrated. 
It was thought to be due to the presence of a monoterpenoid (camphor and 1,8 -
cineole) (Perry et al, 2000). In a small-scale clinical trial in Iran on AD patients with 
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the ethanol extract of Salvia officinalis (Akhondzadeh et al, 2003), it was found that 
AD patients taking salvia extract daily shown to have significant cognitive 
improvement. However, the lead compounds and the mechanism of action for such 
improvement have not been determined. 
4.1.4 Active components from Salvia miltiorrhiza Bge. 
Lipophilic tanshinone compounds are found in the Salvia species. They are classified 
as tanshinone derivatives, which include tanshinone I, tanshinone IIA, tanshinone IIB, 
cryptotanshinone, hydroxytnshinone IIA, methyltanshinonate, isotanshinone I， 
isotanshinone IIA, isocrytotanshinone I，miltirone, methylenetanshinqunone, 
dihydrotanshinone I, 1,2-dihydrotanshinquinone, dehydromiltirone, danshenxinkun A, 
B，C and tanshinone VI. The water extract of Danshen is known to contain 
protocatechualdehyde, caffeic acid, salvianolic acid A,B,C, rosmarinic acid, 
methylrosmarinate, salviol, tanshinol A,B,C, ferruginol, tigogenin, lithospermic acid 
B, ursolic acid, baicalin and vitamin E. 
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4.2 Effects of tanshinone derivatives on AChE 
4.2.1 Materials and Methods 
The effect of six selected compounds of Danshen on human AChE were tested using 
the Ellman assay. The compounds were obtained as mentioned in Section 2.7, 
Chapter 2. Experiments were performed in triplicate with n=2. Data were analyzed 
with two-way ANOVA. 
4.2.2. Results 
Among these compounds, only cryptotanshinone and dihydrotanshinone I showed 
strong AChE inhibition with IC50 about 5-8 i^M and 0.5-0.8 |jM, respectively (Fig 4.1 
& 4.2). Tanshinone I (Fig. 4.2)，on the other hand, showed a modest AChE inhibition 
with an IC50 about 70 ^M while salvianolic acid B, protcatechualdehyde and 
tanshinone IIA had little effect on inhibiting AChE (Fig. 4.1). 
To test the specificity of cryptotanshinone and dihydrotanshinone I towards hAChE, a 
comparative study on the inhibitory profiles of these two drugs against 
butrylcholinesterase (hBuChE) and hAChE was performed. BuChE is concentrated 
in red blood cell and it is named as pseudoesterase as it is highly homologous to 
AChE. In figure 4.3, the FDA approved galanthamine was tested and it was 20% 
more selective to hAChE than to BuChE in nearly all tested concentrations. In 
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Figure 4.4 and 4.5, both cryptotanshinone and dihydrotanshinone I showed higher 
selectivity for hAChE than hBuChE. At IC50, cryptotanshinone was 30% more 
selective to hAChE than to BuChE while dihydrotanshinone I was 50% more 
selective. For cryptotanshinone, as the drug concentration increased, not only the 
inhibition increased, an increase for its selectivity on hAChE was also observed i.e. 
35% more selective on inhibiting hAChE when 80% inhibition had reached. 
Different from cryptotanshinone, dihydrotanshinone I showed a decrease in binding 
on hAChE with drug concentration increased. At 80% inhibition, the selectivity of 
dihydrotanshinone I dropped from the highest 50% to 40%. As a whole, the data 
showed that cryptotanshinone and dihydrotanshinone are highly selective to hAChE 
than to BuChE and they are even more specific to inhibit hAChE than the FDA 
approved galanthamine in the in vitro Ellman assay. 
In order to determine if there is any cytotoxic effects of these drugs to cells on human 
neuroblastoma SH-SY5Y cells and mouse neuronal NIE-115 cells, cytotoxicity of 
these drugs was estimated by counting the number of viable cells through the MTT 
assay. No significant cytotoxicity of cryptotanshinone was found on these two cell 
lines from 1-50 |aM (Fig 4.6 & 4.7). At higher concentration (100 |iM), 
cryototanshinone showed some cytotoxicity to both cell lines. On the other hand, 
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dihydrotanshinone I and tanshinone I exhibited significant cytotoxicity at 
concentration >10 joM and the effects were more profound in NIE-115 cells (Fig. 4.6). 
Tanshinone IIA, salvianic acid B and prochatechualdehyde did not show any obvious 
cytotoxicity at 1-100 i^M. Galanthamine is generally non-toxic to SH-SY5Y cell line, 
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Fig. 4.1 Percentage inhibition of selected Danshen active components on 
hAChE with colorimetric Ellman assay at 415nm. 10 fold dilution was carried out 
to give a final drug concentration of 0.08, 0.8，8 and 80^iM. Bars indicate mean 土 
SEM of n=2 in triplicates. * Indicate P < 0.001 with respect to the inhibition induced 
by salvianolic acid and protocatechualdehyde at all concentrations. ** indicated P < 
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0.001 with respect to the inhibition induced by salvianolic acid and 
protocatechualdehyde at 0.08|LIM. 
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Fig. 4.2 Percentage inhibition of selected Danshen active components on 
hAChE with colorimetric Ellman assay at 415nm. 10-fold dilution was carried out 
to give a final drug concentration of 0.08，0.8, 8 and SOpM. Bars indicate mean 土 
SEM ofn=2 in tripicate. * Indicate P < 0.001 with respect to the inhibition induced by 
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galanthamine at the corresponding concentration. 
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Fig. 4.3 Percentage inhibition of galanthamine on hAChE and hBuChE with 
colorimetric Ellman assay at 415nm. 10-fold dilution was carried out to give a final 
drug concentration of 0.044, 0.44, 4.4 and 44|iM. * Indicate P < 0.001 with 
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Fig. 4.5 Percentage inhibition of dihydrotanshinone I on hAChE and hBuChE 
with colorimetric Ellman assay at 415nm. 10-fold dilution was carried out to give a 
final drug concentration of 0.044, 0.44, 4.4 and 44|aM. * Indicate P < 0.001，** 
indicate P < 0.006 with respect to the comparative inhibition of AChE and BuChE. 
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Fig. 4.8 Cytotoxicity test of galanthamine on human neuronal cell line SH-SY5Y. 
Percentage of cell survival compared to control is calculated. Galanthamine is 
diluted to a final concentration of 20, 100 and 200 i^M. Bars indicate 土 SEM n=2. 
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4.3 Discussion 
This is the first time crytotanhinone and dihydrotanshinone are reported to have in 
vitro hAChE inhibitory activity. Even tanshinone 11 A, tanshinone I， 
cryptotanshinone and dihydrotanshinone I are very similar to each other, they gave 
very different results over the Ellman assay. In fact, tanshinone IIA is structurally 
the same as cryptotanshinone except that it has one more double bond present in its 
fliran ring. [Fig 4.9] Tanshinone I is also structurally similar to dihydrotanshinone I 
with only a different double bond in the furan ring [Fig 4.9]. I therefore hypothesize 
that the presence of double bond in the furan ring may lower the inhibitory effect of 
these compounds in this particular structure. 
Although tanshinone I gives comparatively lower inhibition over hAChE when 
compared with that of cryptotanshinone and dihydrotanshinone I，it still has a higher 
inhibitory activity than tanshinone IIA, salvianic acid B [Fig 4.1 & 4.2] or 
protcatechualdehyde [Fig 4.1]. This may be due to its structural similarity to 
dihydrotanshinone I. Dihydrotanshinone I is more potent and has a lower IC50 (i.e. 
0.5|j.M) than cryptotanshinone (i.e. 5 |aM). This may be due to their structural 
differences. 
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(a) Cryptotanshinone (b) Dihydrotanshinone I 
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Fig. 4.9 Structures of the six selected drugs of Salvia miltiorrhiza Bunge. 
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However, tanshinone I and dihydrotanshinone I are more cytotoxic to our tested cell 
lines. lOuM of both compounds result in 50% of cell death in the mouse neuronal 
neuroblastoma. Nevertheless, as the cytotoxic dose is much higher than the effective 
dose (IC50 was 0.4-0.5|aM for dihydrotanshinone I), the in vitro toxicity may not be a 
problem in clinical uses. Cryptotanshinone is less cytotoxic and severe cell death 
was only observed at 100|aM (IC50 for inhibiting AChE was 4-5 |iM). The 
cytotoxicity is related to the structures of these chemicals. Tanshinone IIA, has a 
structure similar to cryptotanshinone and has lesser cytotoxic activity. On the other 
hand, tanshinone I has a structure similar to dihydrotanshinone I and is more 
cytotoxic. 
As described in section 4.1.3, studies on the cholinesterase inhibitory activities of 
Salvia species have been reported and the focus is on the monopernes or volatile 
components of these herbs (Perry et al, 2000). The inhibition of those volatile 
components from Salvia species over hAChE was not as potent with IC50 of 0.67 mM 
and 0.63 mM for 1,8-cineole and alpha-pinene respectively. The problem may be due 
to the different Salvia species used or the different of plant part used. Extract from the 
whole plant is often used for experiment or treatment in Western countries while 
Danshen in China only means the root of S. miltiorhiza Bunge. Actually, in 
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Traditional Chinese medicine, the whole plant of S. miltiorhiza Bunge, as describe in 
the book "Chinese and related North American herbs", is named as Shi Jian Chuan 
(石見穿 ) . In Chinese medicine, both Danshen and Shi Jian Chuan have effect to 
increase blood flow. Danshen is used to ease hypertension while Shi Jian Chuan is 
used to treat abdominal pain, arthritis inflammation and nasopharyngeal carcinoma 
etc. We can see that Danshen and Shi Jian Chuan process different usages, even 
though they are actually obtained from the same plant. 
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CHAPTER 5 
EXTRACTION OF CRYPTOTANSHINONE FROM SALVIA MILTIORRHIZA 
5.1 Introduction 
Danshen is a herb used in many aspects of Chinese medicine, and there are many 
reports on the extraction of its active components. Generally, the crude organic portions 
were obtained by extraction with 1:1 of ethanol :hexane or other compatible organic 
solvent and the components purified by high performance liquid chromatography 
(HPLC) (Li et al, 2001). In my work, I have used an ethanol based method to purify 
cryptotanshinone and dihydrotanshinone I. A good yield of these two proposed lead 
compounds is important for various experiments and for lowering the cost. 
Active components of Danshen may be extracted from Danshen roots, or from cell 
culture. Transformed cell cultures of Salvia miltiorrhiza were established by infecting 
the sterile plant with Agrobacterium tumefaciens which was than transferred to a 
yeast-extract containing medium to further boost the production of tanshinone (Chen et 
al 1997). The two-cultured method successfully produced a total of 22mg of tanshinone 
from 1 liter culture solution. It can be a possible alternative, other than extracting from 
the limited content of active ingredients from Danshen roots (Yuan et al, 1990, Zhang et 
1995). 
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5.1.1 Reverse phase high performance liquid chromatography (RP-HPLC) 
In order to obtain the chemical profile of Salvia miltiorrhiza, reverse phase high 
performance liquid chromatography (RP-HPLC) can be used. By RP-HPLC, we are 
able to obtain information of the hydrophobicity of compounds and to know the 
chemical composition of the ethanol extract that results in the inhibition of 
acetylcholinesterase in our study. We can also know the amount of active components 
that are present in our crude sample because variations due to sources of herbs are 
always present. 
RP- HPLC operates on the basis of hydrophilicity and lipophilicity. Basically the 
RP-HPLC is composed of the mobile phase and the stationary phase. Compounds 
interact with the hydrophobic stationary phase will remain absorbed until the organic 
mobile phase reaches a concentration that is critical enough to cause desorption of the 
compound. The stationary phase always consists of silica based packings with n-alkyl 
chains covalently bound. For example, C-8 signifies an octyl chain and C-18 an 
octadecyl ligand. The hydrophobicity of the stationary matrix is directly related to its 
ability to hold chemicals or polypeptides. The more hydrophobic is the stationary matrix, 
the tighter the compound is held and the higher is the concentration of the organic 
mobile phase required for the elution. With increasing organic gradient, the hydrophilic 
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compound is eluted more quickly than the hydrophobic one. 
5.2 Materials and Methods 
5.2.1 Extracts of Danshen from different sources for obtaining the chemical 
profile 
Both aqueous and organic extracts of Danshen were prepared as described in chapter 2. 
Unprocessed Danshen from Sichuan from source A (Danshen A), processed Danshen 
from Sichuan from source B (Danshen B), unprocessed Danshen from Sichuan from 
source C (Danshen C) and Danshen from Heibei obtained from Tongrentang (Danshen 
D), were immersed in 70%, 80%, 90% or 100% ethanol for 4 hours in falcon tubes with 
continuous upside down rotations. The samples were then filtered and dried with the 
speedvac machine before subject to lyophilization. The dried samples were diluted to 10, 
50, 100 |ig/mL for Ellman assay. 
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5.2.2 Reverse phase high performance liquid chromatography (RP-HPLC) 
5.2.2.1 Analytical RP-HPLC 
Analytical column (Symmetry® Ci8, 5.0|am, 4.6mm x 150mm Column) was used for the 
generation of chemical profile of Danshen ethanol extract. 20mg of Danshen was 
dissolved in ImL DMSO to give a 20mg/mL of stock. 3\xL of the stock was mixed 
with 27 \xL of 40% Acetonitrite (ACN) (Mallinckrodt AR® Analytical Reagent) in 
0.05% Trifluoroacetic acid (Sigma T-6508) for analysis. 20|_iL of the mixture was 
injected. The programme used is as followed: H2O 
Time (mins) %ACN % H2O Flow (mL/min) 
5 40 60 1.0 
30 90 10 1.0 
32 100 0 1.0 
The gradient rose at 2%/min. 
After each run, the column was washed with the following programme: 
Time (mins) %ACN V0H2O Flow (mL/min) 
5 95 5 1.0 
10 95 5 1.0 
15 0 100 1.0 
20 95 5 1.0 
25 0 100 1.0 
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5.2.2.2 Preparative RP-HPLC 
Preparative column (SymmetryPrep ^^ C i g , 7.0|im, 19mm x 150mm Column) was used 
for scale-up production of active component of interest. The Waters sep-pak© 
cartridge was used to concentrate the portion of interest. 
8mL of ACN was used to dissolve 70mg of Danshen ethanol extract. After that, the 
Waters sep-pak© cartridge was equilibrated with ImL ACN before ImL of the dissolved 
extract was added to the cartridge. The flow through was discarded or re-eluted, 
depended by the color of the elute. Finally, a 65% ACN was added to elute the 
cartridge again and the flow-through, the fraction with our desired product were best 
dissolved in up to 65% CAN and was collected for later use. The 65% elute was dried 
by Speed Vac® Plus SCllOA overnight and then re-dissolved in around ImL DMSO. 
150|aL of the DMSO dissolved elute was mixed with 2850|aL 40% ACN to make up to 
3mL for preparative RP-HPLC injection. 
Scale up program was referenced with the equation provided by the column catalogue 
and the programme used for the analytical HPLC with some modification in the 
calculated time of elution. 
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T prep = t Anal x F Anal/F prep x V prep/V Anal 
where T= time, Prep = preparative column, Anal = Analytical column, F = flow rate, 
V = 71 (column radius)^ x column length 
Time (mins) %ACN % H2O Flow (mL/min) 
10 40 60 5.0 
112 90 10 5.0 
116 100 0 5.0 
The gradient rose at 2%/min. 
After each run, the column was washed with the following programe: 
Time (mins) %ACN % H2O Flow (mL/min) 
5 95 5 5.0 
10 95 5 5.0 
15 0 100 5.0 
20 95 5 5.0 
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Fig 5.1 Preparative HPLC profile of the eluted Danshen A with sep-pak© 
cartridges in 65% ACN. X-axis indicates the elution time for the corresponding 
peak. Y-axis indicates the magnitude of the peak eluted in mAU. 
After the injection of the 65% elute prepared with the sep-pak© cartridges, six major 
peaks were observed (Fig 5.1). They were then dried with method described in 
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Section 5.2.2.2 followed by the Ellman assay. 1 and 0.1 ng extracted active ingredients 
were tested with Ellman assay. 
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Fig 5.2 Inhibitory effect of the major six peaks from the preparative HPLC 
fractions in Ellman assay. Bars indicate mean 土 SEM of n=l in triplicates. 
As from the result shown in Fig. 5.2, fraction 60 has the highest activity among all 
fractions in either amount i.e. 0.1 fig or l^ig. In fact, the retention time of fraction 60 
was corresponded with that of cryptotanshinone (Fig. 5.3) and the amount of l\xg per 
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well make up a finally concentration of 40.7|jM. The percentage inhibition was nearly 
the same as that of the commercially obtained cryptotanshinone (Chapter 4，Fig. 1). 
However, for fraction 45 that has similar retention time as dihydrotanshinone I (Fig. 
5.3), do not give a strong inhibition over hAChE as in the commercially obtained 
dihydrotanshinone I. This may due to technical error that this fraction was a mixture of 
both Peaks 1 and 2 (Fig. 5.1) as the peaks were too close and not easy to be separated. 
Weight (mg) % yield 
Fractions 
45 19.6 2.2 
60 5.2 0.6 
64 1.2 0.14 
70 1.1 0.12 
80 3.6 0.4 
Table 5.1 Amount of Ellman tested fractions purified from 884mg of Danshen 
ethanol extract. 
The yield of the desired active components extracted with the sep-pak® cartridges from 
Danshen A was low (Table 1). The yield of cryptotanshinone i.e. fraction 60 was not 
only around 0.6%. The reasons for such low yield included (1) Possible improvement 
required in the extraction method. (2) The source of Danshen A did not rich in the 
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desired active components i.e. cryptotanshinone and dihydrotanshinone I. In order to 
elucidate these problems, different sources of Danshen and different concentration of 
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Fig 5.3 Analytical HPLC profile of the four consumed active components and 
their corresponding retention time — Cryptotanshinone, tanshinone HA, 
dihydrotanshinone I and tanshinone I. X-axis indicates the elution time for the 
corresponding peak. Y-axis indicates the magnitude of the peak eluted in mAU. 
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5.3.2 Different samples of Danshen contain different amount of active components 
that can exert inhibitory effect on hAChE 
Absolute ethanol 70% ethanol 40% ethanol 
mg 
Danshen A 2.2 80.9 121.75 
Danshen B 2.35 54.55 101.75 
Danshen C 1.3 58.65 95.15 
Danshen D 2.7 55.1 111.3 
Table 5.2 Yield of Danshen extracts by immersing Danshen from different origins 
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Fig. 5.4 Comparative inhibitory effect of Danshen extracts by immersing Danshen 
from different origins in 40% ethanol. Bars indicate mean 土 SEM of n=l in 
triplicates. 
When 40% ethanol was used for extraction, Danshen A gives the highest inhibitory 
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effect on hAChE at all concentrations. However, only 45% inhibition can be given at 
100|ig/mL (Fig. 5.4). When 70% ethanol were used, Danshen A gives the highest 
inhibitory effect on hAChE at all concentrations. Highest 50% inhibition can be given at 
concentration 100|j.g/mL (Fig. 5.5). In absolute ethanol, Danshen A gave the highest 
inhibitory effect on hAChE at all concentrations with highest 80% inhibition given at 
50|ig/mL (Fig. 5.6). 
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Fig 5.5 Comparative inhibitory effect of Danshen extracts from different origins 
immerse with 70% ethanol. Bars indicate mean 土 SEM of n=l in triplicates. 
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Fig. 5.6 Comparative inhibitory effect of Danshen extracts from different origins 
immerse with absolute ethanol. Bars indicate mean 土 SEM of n=l in triplicates. 
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Fig. 5.7 Comparative inhibitory effect of Danshen extracts from Danshen B immerse 
with different concentration of ethanol. Inhibitory effect increases with increasing 
concentration of ethanol use in the extracting process. Bars indicate mean 土 SEM of 
n=l in triplicates. 
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The inhibitory effect on hAChE increased with the increased percentage of ethanol used 
for the extraction (Fig. 5.4-5.6) while the yield decreased dramatically when an 
increased percentage of ethanol was used (Table 1). For example, the yield of Danshen 
A increased from 2.35mg to 54.55mg when the percentage of ethanol used for 
extraction decreased from 100% to 70%. However, the inhibitory effect did not 
increase with the yield. The inhibitory effect for the sample extracted with 70% 
ethanol only gave a 4% inhibition at lOmg/mL concentration while the sample extracted 
with 100% ethanol gave a 70% inhibition at the same concentration (Table 5.6). 
There is also a difference in both the yield and inhibitory effect of Danshen from 
different sources. Danshen D and Danshen A gave the highest yield in absolute 
ethanol while Danshen B gave the lowest yield among all (Table 1). When they were 
tested under Ellman assay, it was found that they actually gave different inhibitory 
effects even at the same concentration or under the same extraction condition. That 
means the active ingredients presence in these samples may be different. So, the 
analytical HPLC profile for each samples extracted with absolute ethanol were obtained 
(Fig. 5.8). The black arrow pointed to the peak that corresponds to the retention time 
of cryptotanshinone. The black arrow pointed to the peak that corresponds to the 
retention time of dihydrotanshinone I. The peak 140mAu is the highest for Danshen B 
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while it is the lowest 50mAu in Danshen C. 
The HPLC profile for Danshen B extracted by different concentration of ethanol was 
surprising. The decrease in ethanol from 100% to 95% dramatically decreased the 
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HPLC of Sichuan Danshen (processed) (Danshen A) extracted with different 
concentration of ethanol 
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Fig 5.9 Effect of ethanol concentration in Danshen B extraction. X-axis indicates 
the elution time for the corresponding peak. Y-axis indicates the magnitude of the 
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peak eluted in mAU. 
5.4 Discussion 
The major peaks found in Danshen D after eluted with sep-pak® cartridges in 65% ACN 
was extracted with Preparative HPLC and their effect on hAChE was tested. As 
predicted, fraction 60, which had the same retention time as the commercially available 
cryptotanshinone, gave the highest inhibition in the Ellman assay. Fraction 45 also 
gave 60% inhibition at Ifig concentration. Fraction 45 had the same retention time as 
dihydrotanshinone I. The peak for fraction 45 was not quite sharp and the inhibition to 
acetylcholinesterase was not as potent as the purchased dihydrotanshinone I. This may 
be due to the presence of more than one component in this peak. 
In large-scale production of Danshen ethanol extract, it is better to balance between the 
amount of effective active components and the actual yield from the extract. High 
yield of extract may not reflect a high content of effective components. To check for 
the active components, colorimetric Ellman assay was used to check for the inhibitory 
capacity of these extracts on hAChE. (Fig 5.4-5.6) 
I first tried to increase the yield by decreasing the percentage of ethanol used. Although 
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the yield of extract increased with decreasing percentage of ethanol used, their 
inhibitory effect on hAChE was also decreased. From the HPLC results, peaks present 
in the sample prepared with 95% ethanol were nearly 100% lower than the one prepared 
with absolute ethanol. When 75% of ethanol was used, the peaks that were found in 
100% ethanol were nearly undetectable. In conclusion, using absolute ethanol for the 
extraction of Danshen is the best to retain the inhibitory capacity. Nevertheless, the 
yield of cryptotanshinone was only around 1% of the total extract. 
The yield may be further optimized. This is because I have only used a small-scale 
extraction test to compare the quality and yield. Suggestions to improve include (1) 
Lengthen the extraction time to 24 hours instead of 8 hours at present. (2) We can 
increase the yield by using vessel with larger surface area during extraction, increase the 
extraction time or even refluxing the sample or (3) performing multiple extraction. 
Starting material is very important in TCM research. In my work, I have found that 
Danshen from different sources contain different amount of active inhibitory 
components. Above all, crude ethanol extract of processed Danshen from Sichuan 
gave the highest inhibitory effect with 10|ig/mL led to 75% of hAChE inhibition (Fig 
5.6) in the colorimetric Ellman assay. This Danshen was smoked by sulphur for 
preservation before sold. This form of Danshen does contain higher amount of desired 
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active components. This is because the non-processed Danshen crude extract gave the 
lowest inhibitory effect with its crude ethanol extract (Fig 5.6, 10|j,g/mL gave 55% 
inhibition). The decrease in inhibition for the non-processed Danshen can also be 
observed from its difference in HPLC profile with the processed Sichuan Danshen (Fig. 
5.8). There is no big difference for their general profile. However, the amount of 
cryptotanshinone and dihydrotanshinone I in these two differently processed Danshen 
were not the same. Danshen from Sichuan contained a higher calculated amount of 
cryptotanshinone (i.e lOfxg) than the non-processed one e.g. Danshen B (i.e. 3.6fig). 
There is also a huge difference between the dihydrotanshinone I content, with processed 
Sichuan Danshen contained 2.2 \xg of dihydrotanshinone I and the non-processed one 
only contained 1.8 ng at the same amount of extract injected. The content of active 
components of non-processed Danshen D, which are also from Sichuan, is also 
comparatively much lower than processed Sichuan Danshen (Danshen B). 
After the HPLC study of these Danshen samples were performed, it was cleared that the 
inhibition of Danshen on acetylcholinesterase was directly related to the amount of 
proposed AChE inhibitors including cryptotanshinone and dihydrotanshinone in these 
extracts. The amount of active components decreased severely when the ethanol 
concentration decreased from 100% to 80% illustrating that although the yield of extract 
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increased with decreasing concentration of ethanol, the amount of the desired active 
components were decreasing. When the concentration of ethanol was lowered, the 
yields of cryptotanshinone and dihydrotanshinone I (Fig 5.8) and the inhibition of 
hAChE were also decreased significantly (Fig 5.9). 
At the very beginning, I had used Danshen D for the Preparative HPLC extraction. 
From Fig 5.8, it is found that Danshen A and C gave a sharp and high peak at 15 
minutes, which is the retention time of dihydrotanshinone I. So, it seemed that, 
Danshen B or D were more appropriate for the extraction of dihydrotanshinone I. 
In the Preparative HPLC study, sep-pak© cartridge was used to elute the designated 
portion where crytotanshinone and dihydrotanshinone I were present. The sep-pak® can 
concentrate the designated portion so as to increase the yield of the desired peaks. 
However, this method causes severe loss of active components during sample elution 
and fractions transferred processes. However, we can increase the yield of the active 
component by choosing the kind of Danshen with the highest content of our desired 
ingredients. Also, the price for Danshen should also be considered. Although the 
content of Danshen B and D, as we can observed from their HPLC profile, did not vary 
much, the price ofDanshen B (HKD$ 80/kg) is much cheaper than D (HKD$330 /kg). 
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It is concluded that, Danshen B should be used later for large-scale extraction of 
cryptotanshinone and dihydrotanshinone I. 
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CHAPTER 6 EFFECT OF CRYPTOTANSHINONE ON CALCIUM 
MOVEMENT EN SH-SY5Y CELLS 
6.1 Introduction 
The change of intracellular calcium level is one of the important cellular regulatory 
switches. Transmitter release, gene expression or excitability of neuronal cells, are 
regulated by calcium level at different degree and level. Changes of calcium can be 
either brought into the cell by ion channel opening or by intracellular store release. 
Nicotinic receptor is an excitatory receptor in mammals and it is present particularly in 
the neuromuscular endplate (Lindstrom et al, 1995). nAChR is a ligand-gated ionic 
channel and its action as a receptor is by regulating the calcium level. Many subtypes 
of these receptors exist in the brain. These different subtypes are the results of different 
combination from at least 12 gene products, namely a2-al0, and (32-(34. Most of them 
exist as a channel by combination with at least 2 subtypes, like a3p2 (Cooper et al, 
1991). aTnAChR is an exception for it can form a functional channel by itself 
(Couturier et al, 1990). This receptor corresponds with the a-bungarotoxin binding 
sites present in the central nervous system and the autonomous nervous system. 
Using nicotinic agonist is a possible approach to up-rise the level of synaptic ACh in 
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AD patients. Galanthamine, as an APL, exerts its effect on nAChR by binding to a site 
distinct to the active site. Since it is not directly bind to the active site, the effect will 
not be compensated by nicotine and results in desensitization. The fact that 
galanthamine does not compete or exert a stimulation by itself over nAChR further 
prove its role as an APL (Zwart, 1997& 2002). The success of galanthamine has led to 
the screening of drugs that retain similar properties, that is - drug can act as a hAChE 
inhibitor and an APL of nicotinic receptor. 
In this experiment, cryptotanshinone that has been tested to be a potential hAChE 
inhibitor in the Ellman assay, will be tested on its ability to modulate nicotinic function. 
Since human neuroblastoma SH-SY5Y cells have been well characterized with the 
presence of nAChR include oc3，oc5,a7,P2 and |34 nAChR subunits which form a3 and 
al subtypes (Wonnacott et al, 2002) of nAChR the cells are therefore appropriate for 
effect of the active components of Danshen on calcium changes. 
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6.2 Materials and Methods 
6.2.1 Reagents and drugs 
Fluo 3-acetyxymethyl ester (AM) and Pluronic F127 were obtained from Molecular 
Probes. Tissue culture media and materials were from GIBCO. Culture plates were 
from Coming. Microscope cover glasses were from Fisherband. Nicotine, 
mecamylamine hydrochloride (MaL) and a-bungarotoxin (from Bungarus multicinctus) 
(a-bgt) were from Sigma. Cryptotanshinone were purchased from the National 
Institute for the Control of Pharmaceutical and Biological Products, State Drug 
Administration, P R. China. 
6.2.2 Calcium fluorimetry 
2x1SH-SY5Y cells were grown overnight on circular disks (Fisher 25 CIR-1) in 
media and condition described in Section 2.2.4 of Chapter 2. After washed once with 
normal physiological saline solution (N-PSS : containing 140mM NaCl, 5mM KCl, 
ImM MgCl2, lOmM glucose, 5mM HEPES andlmM CaCli (pH7.4) to remove the 
growth media, the cells were loaded with fluo 3-AM for 1 h in dark at room temperature 
by incubation with 10|aM of fluo 3-AM and 0.02% Pluronic F127 in N-PSS. After 
loading with the fluo 3-AM dye, cells were washed with dye free N-PSS to remove the 
excess dye. I f intracellular calcium level were measured, Ca^ ^ free PSS (140mM NaCl, 
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5mM KCl, ImM MgCl2, lOmM glucose, 5mM HEPES and 0.2mM EGTA (pH7.4) was 
used for the washing step. The circular disks containing the cells were then pinned in 
chamber that allow the cells to be bathed in 600|aL of either N-PSS or free PSS 
(depending on the types of experiment). The chamber was placed on the stage of an 
inverted microscope (Nikon Diaphot 200)，and the fluorescent signal was recorded by 
the MRC-1000 laser scanning confocal imaging system with MRC-1000 software 
(Bio-Rad). Experiments were performed without flow. All reagents were originally 
dissolved in DMSO and diluted to the required concentration with either N-PSS or Ca^^  
free PSS (depending on the type of solution in the chamber). 200uL of either NPSS or 
free PSS were mixed with 2iiL of drugs in DMSO to make up a final DMSO 
concentration of 0.25%. The mixtures were added at the side of the chamber with gentle 
mixing. As a control, pipetting the bath media with 200uL of either N-PSS or free 
PSS mixing with DSMO gave no change in [Ca]i. 
For the experiments involving inhibitors, MaL and a-bgt stock were dissolved in water. 
The circular disks were incubated with MaL for 15 minutes and a-bgt for 30 minutes as 
mentioned previously (Dajas-Bailador et al, 2002) before drug treatments and signal 
detection. 
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Data analysis was performed with the Confocal Assistant and Metafluor system 
(Bio-Rad). Changes of 20 cells each time were measured and three experiments were 
performed. Changes in [Ca2+]i in response to the drugs were displayed as the ratio of 
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Fig. 6.1 Ca^ ^ changes after addition of nicotine. Red arrow indicates the time of 
nicotine addition. 
Level of calcium changed in SH-SY5Y cells loaded with fluo-3 AM and bathed in 
N-PSS. The raise of calcium was recorded right after the addition of SO i^M nicotine at 
72 seconds [Fig. 6.1]. The result was not due to intracellular calcium release because 
2+ 




In Fig. 6.2, calcium influx was not detected before addition of nicotine at 58 seconds. 
However, after nicotine was added at 72 seconds, a rapid elevation in cytoplasmic 
Ca2+ was detected. The cytoplamsic calcium raised slow down after 80 seconds 
indicating the level of cytoplasmic calcium was depleting with time, since most of the in 
fluxing Ca2+ were recruited to the intracellular storage organ i.e. the ERs and a 
continuous stimulation of nAChR was required to maintain the observable raise of 
cytoplasmic Ca^^ . This indicates the possible desensitization of the nAChR by high 
level of nicotine used (50|xM). 
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Effect of nicotine on SH-SY5Y cells 
• • 
58 sec 86 sec 
• • 
72 sec 260sec 
Fig. 6.2 Effect of nicotine on SH-SY5Y cells. Nicotine was added at time 71 seconds. 
The nicotine stimulated calcium influx was observed right after the addition of nicotine. 
The observed calcium glow reduced at time 86 seconds, indicating the induced nicotinic 
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Fig 6.3 Effect of nicotine on Ca^ ^ influx in cells treated with 100|iM nicotinic 
receptor blockers - mecamylamine and a-bungarotoxin. Arrow indicates the time 
for nicotine addition. 
Effect of nicotine on Ca^ ^ influx in cell treated with nicotinic receptor blockers. 
In Fig. 6.3 Level of calcium did not change significantly in cells pre-incubated with 
lOOjiM mecamylamine for 15 minutes or 30 minutes with lOOnM a-bungarotoxin 
before the experiment. 50 ^iM nicotine was added at 72 seconds (indicated by arrow). 
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Fig. 6.4 Effect of cryptotanshinone on Ca^ ^ movement in cell bathed in N-PSS and 
free PSS. Arrow indicates the time for cryptotanshinone addition. 
Effect of cryptotanshinone on Ca^ ^ movement. The level of calcium did not change 
significantly after the addition of 50 \iM cryptotanshinone at 72 seconds (indicated by 
arrow). SH-SY5Y cells were bathed in N-PSS (Fig. 6.4). Similar result was observed 
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after the addition of 50 \ jM cryptotanshinone at 72 seconds when the cells were bathed 
in Ca2+freePSS. 
Possible dual effect induced by cryptotanshinone on nicotinic evoked Ca^ ^ 
movement. In Fig. 6.5 and Fig. 6.6 addition of SOfoM cryptotanshinone was added at 
72 seconds (indicated by black arrow) and 50 ^iM nicotine was added at 450 seconds 
(indicated by red arrow). SH-SY5Y cells were bathed in N-PSS. Comparing Fig. 6.1 
and Fig. 6.2，the fast increases in calcium influx disappeared; cryptotanshinone 
probably altered the action of nicotine on SH-SY5Y nicotinic receptor. The effect of 
nicotine increased was no longer a fast response, instead, gradual and slow cytoplasmic 
calcium glow that last till 950 seconds was observed. We could see that the addition of 
crytotanshinone result in no significant increase in calcium permeability after its 
addition at 72 seconds and that meant the effect was not induced by cryptotanshinone 
solely. This indicated a continuous stimulation of nAChR was created by a prior 
incubation with cryptotanshinone. Its action eliminated the fast response of nicotine 
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SOfiM C + 50|iM nicotine in N-PSS 
—o— 50mM C + 50mM nicotine (incubate in general nAChR blocker Mai) 
— S O m M C + 50mM nicotine (incubate in a7 nAChR blocker a-bgt) 
Fig 6.5 Possible dual effect induced by cryptotanshinone on nicotinic evoked Ca^ ^ 
movement. Black arrow indicates the time for cryptotanshinone addition. Red arrow 
indicates the time for nicotine addition. The effect can be locked by treated with lOOpM 
nicotinic receptor blockers — lOO^M mecamylamine for 15 minutes (red line) and 




72 sec (addition of crytotanshinone) 600 sec • • 
200 sec 870 sec • • 
440 sec (addition of nicotine) 950 sec 
Fig. 6.6 Effect of cryptotanshinone on nicotine induced Ca^ ^ influx. Cryptotanshinone 
and nicotine were added at time 72 seconds and 440 seconds respectively. The induced 
calcium increase persisted from 600 seconds and the increase of calcium slower down 
from 950 seconds onwards. 
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Effect of nicotinic blockers in cryptotanshinone-nicotine induced effect 
In Fig. 6.5，SH-SY5Y cells were bathed in N-PSS and pre-incubated in lOOnM 
a-bungarotoxin before the addition of 50 pAl cryptotanshinone (black arrow) and 
nicotine at time 72 sec and 450 sec (red arrow) respectively. Both nicotinic receptor 
blockers, mecamylamine and a-bgt, blocked the fast influx of calcium induced by 
nicontine. With mecamylamine induced a stronger inhibitory effect on the 
cryptotanshinone and nicotine induced calcium influx. 
Fig. 6.7 and Fig. 6.8 showed the actual event occurred and recorded by confocal 
microscopy. Mecamylamine is a non-specific nAChR blocker. Pre-incubation of 
mecamylamine resulted in nearly no cytoplasmic increase of calcium after nicotine 
addition at 440 seconds (Fig. 6.7). When al nAChR specific blocker was used (Fig. 
6.8), the reduction in cytoplasmic calcium influx was not as significant as that of using 
mecamylamine. We can speculate that the effect of crytotanshinone-nicotine induced 
calcium increase was not solely due to the stimulation of al nAChR subtypes, but also 
the involvements of other nAChR subtypes. For example, the a3p4 or a3p2subtypes 
that are also densely present in SH-SY5Y cells (Wonnacott et al, 2002). 
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72 sec 600sec 
• • 
200sec 870sec • • 
440sec 950sec 
Fig. 6.7 Effect of general nAChR blocker on cryptotanshinone-nicotine induced 
cytoplasmic calcium increase. The cells were incubated with mecamylamine for 15 
minutes prior to experiment. Cryptotanshinone and nicotine were added at 72 seconds 
and 440 seconds respectively. The non-specific blocker successfully block the 
cryptotanshinone-nicotine induced cytoplasmic calcium increased. 
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72 sec 600sec • • 
200 sec 870sec • • 
440 sec 950 sec 
Fig. 6.8 Effect of a7 specific nAChR blocker on cryptotanshinone-nicotine induced 
cytoplasmic calcium increase. The cells were incubated with a-bungarotoxin for 30 
minutes prior to experiment. Cryptotanshinone and nicotine were added at time 72 
seconds and 440 seconds respectively. The blocking effect is less significant than using 
the general nAChR. Indicating cryptotanshinone-nicotine induced cytoplasmic calcium 
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increase is not solely due to the action on a7 nAChR. 
6.4 Discussion 
When nicotine was added to human neuroblastoma cell SH-SY5Y, a sharp rise of 
calcium was found. The increase in calcium can be concluded as the influx of calcium 
but not from the intracellular store because the sharp peak was not detected when the 
bathing buffer was changed from N-PSS to Ca^ ^ free PSS. This is consistent to 
previous observation on calcium influx upon stimulation of nicotinic receptors (Rathouz 
et al, 1994). 
General nicotinic receptor blocker - mecaylamine was used to elucidate the effect of 
nicotine receptors upon addition of antagonist. Mecaylamine is a non-specific 
antagonist and can block the nAChR generally. From the result, we can see that 
nAChR present in the SH-SY5Y cells were blocked by mecaylamine (Fig. 6.5 and Fig. 
6.7). When a-bungarotoxin was used instead, the nicotine induced calcium rise 
persisted, with lower magnitude than that without addition of blocker. a-Bungarotoxin 
is a specific al nAChR antagonist. It has been reported that opening of such channel 
will induce a large influx of calcium (Cuevas et al, 1998, Fucile et al, 2000). 
a-bungarotoxin successfully reduced the nicotinic induce calcium channel opening. 
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The result is consistent with those of the published findings (Dajas-Bailador et al, 2002). 
Incubation of cryptotanshinone for 6 minutes before the addition of nicotine lengthens 
the effect of nicotinic response. This result may indicate that cryptotanshinone is 
actually imposing a dual effect on the nicotinic response by delaying the nicotine 
induced fast influx of calcium. 
It is hard to deduce the actual amount of calcium that has influxed to the cell by the 
above experimental setup. Calcium fluorimetry with fluo-3 can only give a general 
physiological change of certain drugs on calcium. It is essential to carry out in depth 
study of cryptotanshinone on the amount of calcium production, if it is actually acting 
dually with nicotine. This can be done with calcium mobilization study. Since the action 
of cryptotanshinone can be blocked by a-bungarotoxin, its action on an important AD 
related nicotinic receptor subtypes - aVnAChR can be a target for further study. 
Synaptosomes prepared from rat frontal cerebrocortices enriched in aTnAChR (Wang 
et al, 2000a and b) can be used as a concentrated source of such receptor. Amount of 
calcium influx can be accurately obtained by liquid scintillation counting. 
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CHAPTER 7 GENERAL DISCUSSION 
Acetylcholine (ACh) is an important neurotransmitter responsible for the degradation of 
ACh in the neuronal synapses. Neuronal cell death leads to the loss of ACh producing 
neurons, resulting in severe reduction of ACh in patients at the late stage of AD. The 
rationale behind the development of drugs targeted on inhibiting the action of AChE is 
to retain the level ACh. 
In my work, I first discovered that six out of 45 screened Chinese herbs may inhibit 
AChE. Then I focused on the well-studied herb Danshen, as there are active 
components commercially available. I then found that cryptotanshinone and 
dihydrotanshinone I, might be the key components, which led to inhibitory effect of 
Danshen ethanol extract over AChE. 
7.1 Structure-function relationship of crytotanshinone and dihydrotanshinone I 
The structures of crytotanshinone and dihydrotanshinone I seem to be the crucial for 
their inhibitory and cytotoxic effect (Section 4.3, Chapter 4). Their difference is mainly 
found in the furan ring [Fig. 7 (a)]. 
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o H3C 八 ?\ H3? 
H3C CH3 CH3 
Cryptotanshinone Dihydrotanshinone I 
O CH3 O CH3 
CH3 H3C CH3 
T , Tanshinone IIA Tanshinone I 
Fig. 7.1 Structure of cryptotanshinone, tanshinone HA, dihydrotanshinone I，and 
tanshinone I. 
Crytotanshinone and dihydrotanshinone I has a single bond in the furan ring [Fig 7 (a)] 
On the other hand, tanshinone IIA and tanshinone I have double bond and are unable to 
inhibit hAChE in an extend as crytotanshinone and dihydrotanshinone I do. Another 
active component isolated from Danshen is miltirone. This compound has a structure 
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very similar to cryptotanshinone, only with the furan ring missing. Miltirone may help 
to give more information on the structural basis inhibitory effect of cryptotanshinone 
and dihydrotanshinone I. 
〇 
Miltirone 
Fig. 7.2 Structure of Miltirone 
7.2 Further study on cryptotanshinone and dihydrotanshinone I 
7.2.1 Modulation on nictonic receptor 
aTnAChR is one of the widely distributed nicotinic receptors in the nervous system 
(McGehee & Role�1996). It can be found in hippocampus and cortex, areas innervated 
by the basal forebrain cholinergic neurons. This receptor is proved to have high 
permeability to Ca^ "^  and modulate numerous calcium-dependent functions in the 
nervous system (Quik et al, 1997). It is claimed that ACh can stimulate aTnAChR, 
which then results in the increase its permeability to Ca^ ,^ eliciting and modulate 
numerous calcium-dependent functions in the nervous system and in turn, increase the 
100 
ACh release (McGehee et al, 1995; Gray et al., 1996). 
Since we have found that cryptotanshinone may somehow modulate the nicotinic 
receptor, it is worth to study cryptotanshinone on the amount of calcium production, i f it 
is actually acting dually with nicotine. This can be done with calcium mobilization study. 
Since the action of cryptotanshinone can be blocked by a-bungarotoxin, its action on 
an important AD related nicotinic receptor subtypes - aVnAChR can be a target for 
further study. Synaptosomes prepared from rat frontal cerebrocortices is enriched in 
aVnAChR (Wang et al, 2000a and b) can be used as a concentrated source of such 
receptor. Amount of calcium influx can be accurately obtained by liquid scintillation 
counting on '^ ^Ca. 
7.2.2 Behavioral study on mice 
Morris water maze experimentmay be used to study the spatial memory of rats or mice. 
A hidden platform is placed in a water pool and the rat/mouse has to find its position. 
The rat/mouse is first trained to find the hidden platform. Then, it will be injected with 
cryptotanshinone or dihydrotanshinone. The test usually coupled with the use of a 
neurotransmitter blocker, for example scopolamine, to create a temporary memory loss 
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status. The animal behaviour is recorded and analysed in terms of duration and speed of 
swimming, swimming pattern and time in seeking the platform. 
7.2.3 Large scale production of the desired active components 
I have found that cryptotanshinone and dihydrotanshinone I are the lead compounds in 
exerting the hAChE inhibitory effect. However, the present yield (5.9"^mg 
cryptotanshinone/g of Danshen A) is low and definitely not sufficient for clinical trial. 
Recently, there is a report on the use of S.miltiorrhiza Bunge callus for the isolation of 
cryptotanshinone (Wu et al, 2003). 0.2mg/l of N^-benzyladenine is the best for the in 
vitro synthesis of cryptotanshinone and prolonged incubation (60days) of the callus 
cultures also results in the accumulation of cryptotanshinone. As a result, 4.59mg/g 
callus dry weight of cyptotanshinone is produced. 
7.3 Study on other candidate herbs 
Up to now, I have only studied one of the six herbs that show potent AChE inhibitory 
activity. It is worth to screen from the known active ingredients of other candidate 
herbs For examples, p-sitosterol in Bai Shao, He Shou Wu and Ji Xue Teng and catechin 
in Da Huang and Chi Shao (Table 7.1). P-sitosterol is well-known phytohormones and 
catechin is famous for its antioxidative property (Zhang et al, 2000, Liu et al, 2000). 
102 
By working on these known chemicals and isolating some unknown HPLC peaks in 
these selected herbs, we may discover the chemicals that are responsible for the 
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